Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
estradiol + norethisterone acetate (Novo Nordisk)
- Development stage
- Phase 3
- Lead developer
- Novo Nordisk
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ABT(E2 1 mg / NETA 0.5 mg) is a continuous combined oral hormone replacement therapy consisting of a fixed low-dose combination of estradiol (1 mg) and norethisterone acetate (0.5 mg). Estradiol acts as an agonist at estrogen receptors to alleviate hypoestrogenic symptoms, while norethisterone acetate acts as a progesterone receptor agonist to protect the endometrium from estrogen-induced hyperplasia. In clinical trials, this combination is widely used as a hormonal add-back therapy (ABT) in conjunction with gonadotropin-releasing hormone (GnRH) receptor antagonists (such as linzagolix, relugolix, and elagolix) to counteract the bone mineral density loss and vasomotor symptoms associated with profound estrogen suppression. In China, Bio Genuine is co-developing this combination as an adjunct to linzagolix (BG2109) in Phase III trials for the management of moderate to severe endometriosis-associated pain and heavy menstrual bleeding associated with uterine fibroids.
- Brand names
- ActivellaAmabelzKliovanceLopreezaMimvey
- Other names
- ABT (E2 1 mg / NETA 0.5 mg)ABT(E2 1 mg / NETA 0.5 mg)E2/NETAestradiol + norethindrone acetateestradiol/norethindrone acetateestradiol/norethisterone acetate
02
Targets
AR (Adrenergic receptors)ESR1 (ERα)ESR2 (ERβ)PR (Progesterone receptor)
Beyond the preview
Go deeper on estradiol + norethisterone acetate (Novo Nordisk).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on estradiol + norethisterone acetate (Novo Nordisk).